Mackenzie Financial Corp Purchases Shares of 16,124 Pulmonx Co. (NASDAQ:LUNG)

Mackenzie Financial Corp acquired a new stake in shares of Pulmonx Co. (NASDAQ:LUNG) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 16,124 shares of the company’s stock, valued at approximately $102,000.

Several other hedge funds also recently made changes to their positions in LUNG. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Pulmonx during the second quarter valued at approximately $37,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Pulmonx by 609.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after acquiring an additional 7,316 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Pulmonx in the 2nd quarter worth about $93,000. EntryPoint Capital LLC purchased a new position in shares of Pulmonx in the first quarter worth approximately $102,000. Finally, XTX Topco Ltd purchased a new position in Pulmonx during the 2nd quarter worth approximately $222,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Canaccord Genuity Group increased their price objective on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company decreased their price target on shares of Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Insider Buying and Selling

In other news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the sale, the director now directly owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Pulmonx news, CEO Steven S. Williamson purchased 14,245 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, with a total value of $97,435.80. Following the completion of the transaction, the chief executive officer now directly owns 219,531 shares of the company’s stock, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $8.09, for a total value of $161,800.00. Following the completion of the sale, the director now directly owns 1,111,974 shares in the company, valued at approximately $8,995,869.66. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,351 shares of company stock worth $231,094. 5.70% of the stock is currently owned by insiders.

Pulmonx Trading Down 4.0 %

NASDAQ:LUNG opened at $7.01 on Tuesday. The company has a market capitalization of $272.10 million, a P/E ratio of -4.61 and a beta of 0.64. The stock’s 50 day moving average price is $7.21 and its 200 day moving average price is $7.53. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97. Pulmonx Co. has a 52 week low of $5.46 and a 52 week high of $14.84.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, July 31st. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The company had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. On average, research analysts forecast that Pulmonx Co. will post -1.64 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.